RNXT
RNXT
NASDAQ · Biotechnology

Renovorx Inc

$1.01
+0.00 (+0.00%)
As of Apr 1, 3:50 PM ET ·
Financial Highlights (FY 2026)
Revenue
73.4K
Net Income
-15,297,274
Gross Margin
100.0%
Profit Margin
-20,497.7%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 48.8% 48.8% 48.8%
Operating Margin -25,511.6% 26.8% 30.6% 31.5%
Profit Margin -20,497.7% 20.7% 24.4% 20.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 73.4K 3.79M 3.81M 2.96M
Gross Profit 73.4K 1.85M 1.86M 1.45M
Operating Income -18,733,955 1.02M 1.16M 933.6K
Net Income -15,297,274 783.4K 928.9K 608.3K
Gross Margin 100.0% 48.8% 48.8% 48.8%
Operating Margin -25,511.6% 26.8% 30.6% 31.5%
Profit Margin -20,497.7% 20.7% 24.4% 20.5%
Rev Growth +6.9% +13.5% +17.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 13.03M 11.58M 13.18M
Total Equity 14.21M 15.57M 13.44M
D/E Ratio 0.92 0.74 0.98
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -15,962,037 1.80M 1.92M 1.50M
Free Cash Flow 820.9K 949.0K 713.4K